Jk3 alloantibodies during pregnancy-blood bank management and hemolytic disease of the fetus and newborn risk

BACKGROUND

The Kidd-null phenotype, Jk(a-b-), occurs in individuals who do not express the JK glycoprotein. Jk(a-b-) individuals can make an antibody against the Jk3 antigen, a high-incidence antigen present in more than 99.9% of most populations. This presents many challenges to the blood bank including identification of the antibody, masking of other antibodies, and how to provide transfusion support given the rarity of Jk3-negative blood products. Kidd antibodies may cause acute and delayed hemolytic reactions as well as hemolytic disease of the fetus and newborn (HDFN). In this article, we present a series of four practical cases of pregnant women with the anti-Jk3 alloantibody that demonstrate a range of clinical presentations of Kidd-related HDFN.

STUDY DESIGN AND METHODS

We retrospectively reviewed the clinical and blood bank records for four patients and their newborns encountered at institutions in Tennessee, Missouri, Hawaii, and Guam with an anti-Jk3 identified during pregnancy.

RESULTS

Two cases showed no significant evidence for HDFN, while two cases were of mild-to-moderate severity requiring early delivery due to elevated middle cerebral artery (MCA) flow velocities but requiring only phototherapy for hyperbilirubinemia. No intrauterine or neonatal transfusions were necessary. Anti-Jk3 alloantibody titers ranged from 2 to 128.

CONCLUSION

Clinical manifestations of anti-Jk3 HDFN are generally mild to moderate. Anti-Jk3 titers were not found to correlate directly with HDFN severity. We suggest a titer of 16 to 32 as a cutoff for implementing enhanced monitoring of fetal MCA flow velocities, as such titers may be indicative of elevated HDFN risk.

Ten-year retrospective review of transfusion practices in beating-heart organ donors

BACKGROUND

Recent studies suggest that restrictive transfusion strategies are equivocal or noninferior to liberal strategies in various patient populations; however, evidence for the optimal transfusion threshold or current transfusion practice in beating-heart organ donors is lacking. A 10-year retrospective analysis of blood product utilization in beating-heart organ donors was performed to determine current transfusion practice.

STUDY DESIGN AND METHODS

An institutional review board-approved retrospective review of 439 beating-heart organ donors from January 1, 2004, to October 1, 2014, was performed. For each donor, hemoglobin (Hb), platelet (PLT), prothrombin time/international normalized ratio (PT/INR), and fibrinogen levels as well as all transfusion reaction reports were recorded from the time of declaration of brain death to organ procurement.

RESULTS

Red blood cell transfusion occurred in 304 donors (69.2%), with a trough Hb level of more than 8 g/dL in 63.2% and more than 10 g/dL in 15.8%; final Hb was more than 10 g/dL in 44.1% of transfused donors. PLT transfusion occurred in 165 donors (37.6%), with a trough PLT count of more than 50 × 10(9) /L in 113 (68.5%) and more than 100 × 10(9) /L in 15 (9.1%). Plasma transfusion occurred in 217 donors (49.4%), with a peak INR of less than 1.5 in 75 donors (34.6%) and a peak INR of 1.6 to 2.0 in 112 donors (51.6%). Only 17.4% of donors who received cryoprecipitate had fibrinogen levels measured, and results were all more than 200 mg/dL. Transfusion reactions were underreported (p = 0.0001).

CONCLUSIONS

This study suggests potential suboptimal use of limited biologic resources in beating-heart organ donors, as well as significant underreporting of suspected transfusion reactions. Additional studies are indicated to determine optimal transfusion thresholds in this population.

Images in clinical medicine: Morphologic changes in erythrocytes in hypertriglyceridemia

A 39-year-old woman with a history of gestational diabetes was admitted with epigastric pain from acute pancreatitis. She had no history of hyperlipidemia, but multiple blood samples were grossly lipemic, and serum triglyceride levels were markedly increased.

Case report of pancreatic dermoid cyst: can fine needle aspiration make the diagnosis?

CONTEXT

Pancreatic dermoid cysts are rare, benign, germ cell tumors and part of the differential diagnosis for cystic neoplasms of the pancreas.

CASE REPORT

A 35-year-old man presented with an incidentally discovered, 2 cm cystic pancreatic neoplasm of the pancreatic tail identified on CT scan. Endoscopic ultrasound (EUS) revealed a complex, honeycomb lesion. Fine needle aspiration (FNA) yielded a sample of whitish, necrotic material containing histiocytes, benign epithelial cells, and lymphocytes. After distal pancreatectomy and splenectomy was performed, histology revealed a cyst lined by stratified squamous epithelium with benign sebaceous units consistent with a pancreatic dermoid cysts.

DISCUSSION

Although axial imaging reliably detects cystic neoplasms of the pancreas, diagnostic criteria for rare lesions are lacking; therefore alternative modalities such as EUS/FNA can be utilized. This case report highlights the EUS and FNA findings associated with pancreatic dermoid cysts.